Venous thrombosis associated with HMG-CoA reductase inhibitors

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 515-532

  Lippi, Giuseppe ^a   Favaloro, Emmanuelj ^b   Sanchis Gomar, Fabian ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

C reactive protein; HMG CoA reductase inhibitors; statin; therapy; venous thrombosis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBIN;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; COMPETITIVE INHIBITION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM; INFLAMMATION; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84879089413     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343892     Document Type: Article

References (94)

1. Lippi G., Franchini M., Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol: 2011; 8 9 502 512
2. Gotto A. M. Jr, Moon J. E. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol: 2012; 110 1 (Suppl): 3A 14A
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation: 2002; 106 25 3143 3421
4. Matsuyama H., Sato K., Nakamura Y., Suzuki K., Akiba Y. Modulation of regulatory factors involved in cholesterol metabolism in response to feeding of pravastatin- or cholesterol-supplemented diet in chickens. Biochim Biophys Acta: 2005; 1734 2 136 142
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation: 2004; 109 23 01 III39 III43
6. Zhou Q., Liao J. K. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J: 2010; 74 5 818 826
7. Stolla D., Dariolia R., Rodondia N. Lipid-lowering therapies and liver enzymes. Kardiovaskuläre Medizin: 2009; 12 9 239 244
8. Pella D., Rybar R., Mechirova V. Pleiotropic effects of statins. Acta Cardiol Sin: 2005; 21 190 198
9. Lippi G., Favaloro E. J. Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. Semin Thromb Hemost: 2012; 38 2 125 128
10. Lippi G., Franchini M., Favaloro E. J. Unsuspected triggers of venous thromboembolism-trivial or not so trivial? Semin Thromb Hemost: 2009; 35 7 597 604
11. Lippi G., Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost: 2008; 34 8 747 761
12. Tufano A., Coppola A., Cerbone A. M., Ruosi C., Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost: 2011; 37 3 252 266
13. Lippi G., Favaloro E. J., Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost: 2011; 37 3 237 251
14. Bikdeli B., Sharif-Kashani B. Prophylaxis for venous thromboembolism: a great global divide between expert guidelines and clinical practice? Semin Thromb Hemost: 2012; 38 2 144 155
15. Poredos P., Jezovnik M. K. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost: 2011; 37 8 897 902
16. Ray J. G., Rosendaal F. R. The role of dyslipidemia and statins in venous thromboembolism. Curr Control Trials Cardiovasc Med: 2001; 2 4 165 170
17. Goldhaber S. Z., Savage D. D., Garrison R. J., et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med: 1983; 74 6 1023 1028
18. Goldhaber S. Z., Grodstein F., Stampfer M. J., et al. A prospective study of risk factors for pulmonary embolism in women. JAMA: 1997; 277 8 642 645
19. Kawasaki T., Kambayashi J., Ariyoshi H., Sakon M., Suehisa E., Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res: 1997; 88 1 67 73
20. McColl M. D., Sattar N., Ellison J., et al. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis: 2000; 11 3 225 229
21. Nowak-Göttl U., Junker R., Hartmeier M., et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation: 1999; 100 7 743 748
22. von Depka M., Nowak-Göttl U., Eisert R., et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood: 2000; 96 10 3364 3368
23. Lippi G., Bassi A., Brocco G., Manzato F., Marini M., Guidi G. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study. Haematologica: 1999; 84 8 726 729
24. Ignatescu M., Kostner K., Zorn G., et al. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Thromb Haemost: 1998; 80 2 231 232
25. Evans N. S., Green D. ASH evidence-based guidelines: statins in the prevention of venous thromboembolism. Hematology (Am Soc Hematol Educ Program): 2009; 273 274
26. Glynn R. J., Danielson E., Fonseca F. A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med: 2009; 360 18 1851 1861
27. Ramcharan A. S., Van Stralen K. J., Snoep J. D., Mantel-Teeuwisse A. K., Rosendaal F. R., Doggen C. J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost: 2009; 7 4 514 520
28. Sorensen H. T., Horvath-Puho E., Sogaard K. K., et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost: 2009; 7 4 521 528
29. Li L., Sun T., Zhang P., Tian J., Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev: 2011; 12 CD008203
30. Herrington D. M., Vittinghoff E., Lin F., et al. HERS Study Group Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation: 2002; 105 25 2962 2967
31. Ray J. G., Mamdani M., Tsuyuki R. T., Anderson D. R., Yeo E. L., Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med: 2001; 161 11 1405 1410
32. Agarwal V., Phung O. J., Tongbram V., Bhardwaj A., Coleman C. I. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract: 2010; 64 10 1375 1383
33. Squizzato A., Galli M., Romualdi E., et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J: 2010; 31 10 1248 1256
34. Lacut K., Le Gal G., Abalain J. H., Mottier D., Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res: 2008; 122 3 314 319
35. Smeeth L., Douglas I., Hall A. J., Hubbard R., Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol: 2009; 67 1 99 109
36. Huerta C., Johansson S., Wallander M. A., García Rodríguez L. A. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med: 2007; 167 9 935 943
37. Doggen C. J., Lemaitre R. N., Smith N. L., Heckbert S. R., Psaty B. M. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost: 2004; 2 5 700 701
38. Yang C. C., Jick S. S., Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol: 2002; 53 1 101 105
39. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA: 1975; 231 4 360 381
40. Keech A., Simes R. J., Barter P., et al. FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet: 2005; 366 9500 1849 1861
41. Freeman D. J., Robertson M., Ford I., et al. Risk factors for the development of incident venous thrombotic events in the prospective study of pravastatin in the elderly at risk (PROSPER). (Abstract) Platelets: 2007; 18 01 S18
42. Yang C. C., Kao C. C. Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control study. J Chin Med Assoc: 2007; 70 3 103 109
43. Rodriguez A. L., Wojcik B. M., Wrobleski S. K., Myers D. D. Jr, Wakefield T. W., Diaz J. A. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis: 2012; 33 4 371 382
44. Khemasuwan D., Divietro M. L., Tangdhanakanond K., Pomerantz S. C., Eiger G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med: 2010; 123 1 60 65
45. Lacut K., Oger E., Le Gal G., et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol: 2004; 18 4 477 482
46. Momi S., Impagnatiello F., Guzzetta M., et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol: 2007; 570 1-3 115 124
47. Pai M., Evans N. S., Shah S. J., Green D., Cook D., Crowther M. A. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res: 2011; 128 5 422 430
48. Resh M., Mahmoodi B. K., Navis G. J., Veeger N. J., Lijfering W. M. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res: 2011; 127 5 395 399
49. Delluc A., Tromeur C., Le Moigne E., et al. Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res: 2012; 130 6 859 863
50. Delluc A., Malécot J. M., Kerspern H., et al. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis: 2012; 220 1 184 188
51. Macchia A., Laffaye N., Comignani P. D., et al. Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS ONE: 2012; 7 3 e32894
52. Rahimi K., Bhala N., Kamphuisen P., et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med: 2012; 9 9 e1001310
53. Freeman D. J., Robertson M., Brown E. A., et al. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatr: 2011; 11 8
54. Downs J. R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA: 1998; 279 20 1615 1622
55. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med: 1998; 339 19 1349 1357
56. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet: 2002; 360 9326 7 22
57. Sever P. S., Dahlöf B., Poulter N. R., et al. ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet: 2003; 361 9364 1149 1158
58. Fellström B., Holdaas H., Jardine A. G., et al. Assessment of Lescol in Renal Transplantation Study Investigators Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int: 2004; 66 4 1549 1555
59. Colhoun H. M., Betteridge D. J., Durrington P. N., et al. CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet: 2004; 364 9435 685 696
60. Asselbergs F. W., Diercks G. F., Hillege H. L., et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation: 2004; 110 18 2809 2816
61. Koren M. J., Hunninghake D. B. ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol: 2004; 44 9 1772 1779
62. Wanner C., Krane V., März W., et al. German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med: 2005; 353 3 238 248
63. Cowell S. J., Newby D. E., Prescott R. J., et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med: 2005; 352 23 2389 2397
64. Nakamura H., Arakawa K., Itakura H., et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet: 2006; 368 9542 1155 1163
65. Knopp R. H., d'Emden M., Smilde J. G., Pocock S. J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care: 2006; 29 7 1478 1485
66. Amarenco P., Bogousslavsky J., Callahan A. III., et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med: 2006; 355 6 549 559
67. Kjekshus J., Apetrei E., Barrios V., et al. CORONA Group Rosuvastatin in older patients with systolic heart failure. N Engl J Med: 2007; 357 22 2248 2261
68. Sola S., Mir M. Q., Lerakis S., Tandon N., Khan B. V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol: 2006; 47 2 332 337
69. Tavazzi L., Maggioni A. P., Marchioli R., et al. Gissi-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet: 2008; 372 9645 1231 1239
70. Crouse J. R. III, Raichlen J. S., Riley W. A., et al. METEOR Study Group Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA: 2007; 297 12 1344 1353
71. Feldman H. H., Doody R. S., Kivipelto M., et al. LEADe Investigators Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology: 2010; 74 12 956 964
72. Chan K. L., Teo K., Dumesnil J. G., Ni A., Tam J. ASTRONOMER Investigators Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation: 2010; 121 2 306 314
73. Fassett R. G., Robertson I. K., Ball M. J., Geraghty D. P., Coombes J. S. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis: 2010; 213 1 218 224
74. Smilde T. J., van Wissen S., Wollersheim H., Trip M. D., Kastelein J. J., Stalenhoef A. F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet: 2001; 357 9256 577 581
75. de Lemos J. A., Blazing M. A., Wiviott S. D., et al. Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA: 2004; 292 11 1307 1316
76. Nissen S. E., Tuzcu E. M., Schoenhagen P., et al. REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA: 2004; 291 9 1071 1080
77. Cannon C. P., Braunwald E., McCabe C. H., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med: 2004; 350 15 1495 1504
78. LaRosa J. C., Grundy S. M., Waters D. D., et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med: 2005; 352 14 1425 1435
79. Pedersen T. R., Faergeman O., Kastelein J. J., et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA: 2005; 294 19 2437 2445
80. Armitage J., Bowman L., Wallendszus K., et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet: 2010; 376 9753 1658 1669
81. Rosendaal F. R. Statins and venous thrombosis: a story too good to be true? PLoS Med: 2012; 9 9 e1001311
82. Ridker P. M., Cannon C. P., Morrow D., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy. N Engl J Med: 2005; 352 1 20 28
83. Ridker P. M., Danielson E., Fonseca F. A., et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med: 2008; 359 21 2195 2207
84. Lippi G., Favaloro E. J., Montagnana M., Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med: 2010; 48 12 1693 1701
85. Perez A., Bartholomew J. R. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Cleve Clin J Med: 2010; 77 3 191 194
86. Cervellin G., Comelli I., Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med: 2010; 48 6 749 756
87. Undas A., Brummel-Ziedins K. E., Mann K. G. Statins and blood coagulation. Arterioscler Thromb Vasc Biol: 2005; 25 2 287 294
88. Kinlay S. Potential vascular benefits of statins. Am J Med: 2005; 118 Suppl 12A 62 67
89. Liao J. K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol: 2005; 45 89 118
90. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb: 2003; 10 3 140 144
91. Wierzbicki A. S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther: 2003; 99 1 95 112
92. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol: 2012; 73 4 518 535
93. Mihos C. G., Salas M. J., Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev: 2010; 18 6 298 304
94. Mihos C. G., Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med: 2011; 4 261 271